



April 30, 2015

## **Corium to Report Second Quarter Fiscal 2015 Financial Results on Thursday, May 7, 2015**

MENLO PARK, Calif., April 30, 2015 (GLOBE NEWSWIRE) -- Corium International, Inc. (Nasdaq:CORI) today announced that it will report financial results for the Second Quarter Fiscal 2015 on Thursday, May 7, 2015 after the close of the U.S. financial markets. Corium will host a conference call and live audio webcast at 5:15 p.m. Eastern time, 2:15 p.m. Pacific time to discuss its financial results.

### **Conference Call and Webcast Details**

Investors and analysts can access the call toll-free by dialing 844-831-3024 (United States) or +1 315-625-6887 (international). The conference ID # is 38599865. The conference call will also be available via a live audio webcast on the Investors section of Corium's website at <http://ir.coriumgroup.com/events.cfm>. Please access the website 10 minutes prior to the start of the call to ensure adequate time for any software downloads that may be necessary. A replay of the conference call will be available for two weeks and may be accessed by dialing toll-free 855-859-2056 (United States) or +1 404-537-3406 (international) and entering the conference ID # 38599865 or by visiting Corium's website.

### **About Corium**

Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage the company's advanced transdermal and transmucosal delivery systems. Corium has developed and is the sole commercial manufacturer of six prescription drug and consumer products with partners Teva Pharmaceuticals, Par Pharmaceutical and Procter & Gamble. The company has two proprietary transdermal platforms: Corplex™ for small molecules and MicroCor®, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. The company's late-stage pipeline includes a contraceptive patch co-developed with Agile Therapeutics that is currently in Phase 3 trials, and additional transdermal products that are being co-developed with Teva. Corium has multiple proprietary programs in preclinical and clinical development for the treatment of osteoporosis and neurological disorders. For further information, please visit [www.coriumgroup.com](http://www.coriumgroup.com).

CONTACT: Investor and Media Contact:

Karen L. Bergman

BCC Partners

kbergman@bccpartners.com

(650) 575-1509